Compare NFE & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | GLSI |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 372.0M |
| IPO Year | 2018 | 2020 |
| Metric | NFE | GLSI |
|---|---|---|
| Price | $0.59 | $22.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.70 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 20.3M | 131.3K |
| Earning Date | 05-11-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,364,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $89.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $7.78 |
| 52 Week High | $7.05 | $34.10 |
| Indicator | NFE | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 27.37 | 41.27 |
| Support Level | $0.56 | $21.20 |
| Resistance Level | $1.38 | $30.02 |
| Average True Range (ATR) | 0.11 | 1.87 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 5.07 | 15.54 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.